Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.46 |
| ▸ | TOP1 | P11387 | 2/20 | 0.42 |
| ▸ | HRAS | P01112 | 3/20 | 0.42 |
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23728539 | 1.00 | HDAC1 (0.57) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL27346944 | 0.96 | HDAC1 (0.62) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL30125592 | 0.96 | HDAC1 (0.62) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL25809050 | 0.96 | HDAC1 (0.57) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL30125590 | 0.95 | HDAC1 (0.55) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL26553382 | 0.95 | HDAC1 (0.55) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL23728853 | 0.94 | HDAC1 (0.57) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL31615222 | 0.94 | HDAC1 (0.51) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL23728551 | 0.94 | HDAC1 (0.56) | HDAC1HDAC2HDAC8ERBB2TOP1 | |
| SCHEMBL30125624 | 0.93 | HDAC1 (0.61) | HDAC1HDAC2HDAC8ERBB2TOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295632-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. | 2025-09-25 | — | — | US | disclosed |
| WO-2025122764-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | Design Therapeutics, Inc. (US) | 2025-06-12 | — | — | WO | disclosed |
| EP-4539839-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | Design Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4539842-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | Design Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025076181-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2025076236-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20250109132-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | DESIGN THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | disclosed |
| EP-4522168-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-4504339-A2 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4460302-A2 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| WO-2023133284-A2 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133284-A2 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2023-07-13 | — | — | WO | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| CN-115768765-A | Methods and compounds for treating genetic diseases | 设计治疗公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2023014793-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-4100404-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | HDAC1 551/4885HDAC2 1636/4885HDAC8 441/4885 |
| US-20250295632-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | ATXN2, CLN6, ATXN2L | HDAC1 844/4885HDAC2 585/4885HDAC8 225/4885 |
| US-20250109132-A1 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | ATXN2, ATXN2L, ATXN10 | HDAC1 569/4885HDAC2 1062/4885HDAC8 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.